The purpose of this study is to evaluate the efficacy of a polypill strategy containing aspirin (100 mg), ramipril (2.5, 5 or 10 mgs), and atorvastatin (40 mgs) compared with the standard of care (usual care according to the local clinical practices at each participating country) in secondary prevention of major cardiovascular events (cardiovascular death, nonfatal myocardial infarction, nonfatal ischemic stroke, and urgent revascularization) in elderly patients with a recent myocardial infarction.
Disease: Cardiovascular disease
Study phase: III
ECRIN support role: Local pharmacovigilance
Study/trial status: Start-up phase
Actual trial start date: 17/05/2016
Expected patient number: 3206 patients
Sponsor: Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC)
Sponsor type: Academic
Principal investigator (PI): Valentín Fuster
Current participating countries: